Alzamend Neuro, Inc. (ALZN): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALZN Stock Price Chart Interactive Chart >
ALZN Price/Volume Stats
|Current price||$0.94||52-week high||$33.55|
|Prev. close||$0.91||52-week low||$0.80|
|Day high||$1.02||Avg. volume||1,420,954|
|50-day MA||$1.04||Dividend yield||N/A|
|200-day MA||$1.86||Market Cap||84.86M|
Alzamend Neuro, Inc. (ALZN) Company Bio
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Most Popular Stories View All
ALZN Latest News Stream
|Loading, please wait...|
ALZN Latest Social Stream
View Full ALZN Social Stream
Latest ALZN News From Around the Web
Below are the latest news stories about Alzamend Neuro Inc that investors may wish to consider to help them evaluate ALZN as an investment opportunity.
By John Vandermosten, CFA NASDAQ:ALZN Alzheimer’s Disease (AD) is a feared diagnosis that afflicts many older individuals, particularly women and those with a genetic predisposition for the condition. AD is so frightening in large part because there have been no effective treatments approved for it, despite a dramatic need. With near six million Americans living with AD, growing to an anticipated
In a report issued on December 17, James Jang from Univest Securities maintained a Buy rating on Alzamend Neuro (ALZN – Research Report), with a price target of $15.00. The company's shares closed last Friday at $2.45, close to its 52-week low of $1.87. Jang has an average return of 4.4% when recommending Alzamend Neuro. According to TipRanks.com, Jang is ranked #7554 out of 7739 analysts. Currently, the analyst consensus on Alzamend Neuro is a Moderate Buy with an average price target of $11.50.
Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate
Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determine the pharmacokinetics, safety, and tolerability of AL001 and target doses for a planned Phase 2 study in Alzheimer's patients. Related Link: See Why Alzamend Neuro Stock Is Rallying On Thursday. The participants received a single dose of AL001 containing lithium equivalent to 150 mg lithium carbona
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
TAMPA, Fla., December 17, 2021--Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
We're at the halfway point of the week but there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday!
ALZN Price Returns